Conference Advisory Committee
Xiaoyuan (Shawn) Chen, PhD
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Dr. Xiaoyuan (Shawn) Chen received his PhD in Chemistry from the University of Idaho (1999). After two postdocs at Syracuse University and Washington University in St. Louis, he started his Assistant Professorship in 2002 and then moved to Stanford in 2004. He moved to NIH in 2009 and became a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH. His current research interests include development of molecular imaging toolbox for better understanding of biology, early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development. His lab puts special emphasis on high-sensitivity nanosensors for biomarker detection and theranostic nanomedicine for imaging, gene and drug delivery, and monitoring of treatment. Dr. Chen has published over 700 peer-reviewed papers (H-index = 127, total citations > 57,000 based on Google Scholar) and numerous books and book chapters. He is the founding editor of journal “Theranostics” (2017 IF = 8.537). He was elected as AIMBE Fellow (2017), received Michael J. Welch, PhD Award (2019), ACS Bioconjugate Chemistry Lecturer Award (2016), NIH Director’s Award (2014) and NIBIB Mentor Award (2012).
Mustafa Culha, PhD
Yeditepe University, Turkey
Dr. Culha is a full professor in Genetics and Bioengineering in the Department of Yeditepe University. He is also the founder of its Nanobiotechnology and Molecular Engineering Research group, which was established in 2004. He obtained his master's degree in Chemistry at Wake Forest University in North Carolina and later pursued his PhD in Chemistry at the University of Tennessee in Knoxville. His research interests include applications of surface-enhanced Raman scattering in cancer diagnosis and clinical pathogen detection and indentification; synthesis, self-assembly and applications of novel nanomaterials and nanocarriers for delivery of cancer therapeutics; and nanomedicine and nanomaterial surface chemistry nanotoxicity relationships. He has established 5 patents.
Jagat Kanwar, PhD
Deakin University, Australia
Professor Jagat R Kanwar is the Head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (LIMBR). He received his Master’s degree in Medical Biochemistry and PhD in Molecular Immunology. He has an international reputation and expertise in investigating fundamental and applied molecular signaling aspects of pathogenesis of cancer and chronic inflammatory diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 110 publications in peer reviewed international journals, 17 book chapters and 3 edited books. He serves as an Editor, Reviewer and Editorial Advisory Board Member of more than 45 international journals, invited speaker in more than 50 conferences and chaired conferences sessions on Cancer, Immunology, Vaccines, Microbial infections, Nanotechnology, Nanomedicine and Biotechnology.
Donald Martin, PhD
Universite Grenoble Alpes, France
After completing postdoctoral training at Sydney University as the inaugural Medical Foundation Post-Doctoral Fellow (1988-91), Dr. Martin established patch-clamp electrophysiology laboratories at St Vincent’s Hospital and the University of Technology, Sydney. He has more than 100 publications in scientific journals and a book on nanobiotechnology published by Springer, which is now translated into Russian and published by Nauchny Mir, Moscow. His an author on more than 8 patents, and is a co-founder of the startup company, Seagull Technology Pty Ltd that develops novel devices for the non-invasive delivery of drugs to the eye, and he is Chairman of another startup company, SDx Tethered Membranes Pty Ltd that develops nanostructured devices based on biomimetic membrane technology. He is also on the scientific advisory board of the startup French company, Synthelis SAS. Don initiated the formation of the Australian network in nanobiotechnology called OzNano2Life, which was funded in 2004 by the International Science Linkages program under the Australian Government’s innovation statement Backing Australia’s Ability.